

J Hans Devries

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2010691/publications.pdf>

Version: 2024-02-01

115
papers

11,225
citations

76196

40
h-index

30848

102
g-index

117
all docs

117
docs citations

117
times ranked

9422
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. <i>Diabetes Care</i> , 2019, 42, 1593-1603.	4.3	2,101
2	International Consensus on Use of Continuous Glucose Monitoring. <i>Diabetes Care</i> , 2017, 40, 1631-1640.	4.3	1,376
3	Glucose variability is associated with intensive care unit mortality*. <i>Critical Care Medicine</i> , 2010, 38, 838-842.	0.4	916
4	Practical recommendations for the management of diabetes in patients with COVID-19. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 546-550.	5.5	680
5	Retinal neurodegeneration may precede microvascular changes characteristic of diabetic retinopathy in diabetes mellitus. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E2655-64.	3.3	442
6	Glucose Variability; Does It Matter?. <i>Endocrine Reviews</i> , 2010, 31, 171-182.	8.9	364
7	Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 355-366.	5.5	288
8	Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): a randomised, open-label, crossover trial. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 893-902.	5.5	284
9	The Management of Type 1 Diabetes in Adults. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetes Care</i> , 2021, 44, 2589-2625.	4.3	244
10	Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Injections: The impact of baseline A1c. <i>Diabetes Care</i> , 2004, 27, 2590-2596.	4.3	222
11	Outcome Measures for Artificial Pancreas Clinical Trials: A Consensus Report. <i>Diabetes Care</i> , 2016, 39, 1175-1179.	4.3	195
12	2 month evening and night closed-loop glucose control in patients with type 1 diabetes under free-living conditions: a randomised crossover trial. <i>Lancet Diabetes and Endocrinology</i> , 2015, 3, 939-947.	5.5	189
13	Glucose Variability: Where It Is Important and How to Measure It. <i>Diabetes</i> , 2013, 62, 1405-1408.	0.3	186
14	A Randomized Trial of Continuous Subcutaneous Insulin Infusion and Intensive Injection Therapy in Type 1 Diabetes for Patients With Long-Standing Poor Glycemic Control. <i>Diabetes Care</i> , 2002, 25, 2074-2080.	4.3	174
15	Hypoglycemia is associated with intensive care unit mortality*. <i>Critical Care Medicine</i> , 2010, 38, 1430-1434.	0.4	172
16	Insulin Degludec in Type 1 Diabetes: A randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine. <i>Diabetes Care</i> , 2011, 34, 661-665.	4.3	156
17	COVID-19 and metabolic disease: mechanisms and clinical management. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 786-798.	5.5	155
18	Sequential Intensification of Metformin Treatment in Type 2 Diabetes With Liraglutide Followed by Randomized Addition of Basal Insulin Prompted by A1C Targets. <i>Diabetes Care</i> , 2012, 35, 1446-1454.	4.3	145

#	ARTICLE	IF	CITATIONS
19	Accuracy and Longevity of an Implantable Continuous Glucose Sensor in the PRECISE Study: A 180-Day, Prospective, Multicenter, Pivotal Trial. <i>Diabetes Care</i> , 2017, 40, 63-68.	4.3	141
20	The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetologia</i> , 2021, 64, 2609-2652.	2.9	128
21	Rate of Hypoglycemia in Insulin-Treated Patients with Type 2 Diabetes Can Be Predicted from Glycemic Variability Data. <i>Diabetes Technology and Therapeutics</i> , 2012, 14, 1008-1012.	2.4	106
22	Comparison of a Needle-Type and a Microdialysis Continuous Glucose Monitor in Type 1 Diabetic Patients. <i>Diabetes Care</i> , 2005, 28, 2871-2876.	4.3	105
23	Day-and-Night Closed-Loop Glucose Control in Patients With Type 1 Diabetes Under Free-Living Conditions: Results of a Single-Arm 1-Month Experience Compared With a Previously Reported Feasibility Study of Evening and Night at Home. <i>Diabetes Care</i> , 2016, 39, 1151-1160.	4.3	98
24	Real-Time Improvement of Continuous Glucose Monitoring Accuracy: The smart sensor concept. <i>Diabetes Care</i> , 2013, 36, 793-800.	4.3	86
25	Insulin treatment guided by subcutaneous continuous glucose monitoring compared to frequent point-of-care measurement in critically ill patients: a randomized controlled trial. <i>Critical Care</i> , 2014, 18, 453.	2.5	80
26	A Decrease in Glucose Variability Does Not Reduce Cardiovascular Event Rates in Type 2 Diabetic Patients After Acute Myocardial Infarction. <i>Diabetes Care</i> , 2011, 34, 855-857.	4.3	79
27	Continuous glucose monitoring during diabetic pregnancy (GlucoMOMS): A multicentre randomized controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1894-1902.	2.2	77
28	Premeal Injection of Rapid-Acting Insulin Reduces Postprandial Glycemic Excursions in Type 1 Diabetes. <i>Diabetes Care</i> , 2010, 33, 2152-2155.	4.3	75
29	Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: Insights from a patient-level pooled analysis of six randomized clinical trials. <i>Journal of Diabetes and Its Complications</i> , 2014, 28, 399-405.	1.2	75
30	Feasibility of a Portable Bihormonal Closed-Loop System to Control Glucose Excursions at Home Under Free-Living Conditions for 48 Hours. <i>Diabetes Technology and Therapeutics</i> , 2014, 16, 131-136.	2.4	69
31	A Critical Appraisal of the Continuous Glucose-Error Grid Analysis. <i>Diabetes Care</i> , 2006, 29, 1805-1811.	4.3	62
32	A randomized, multicentre trial evaluating the efficacy and safety of fast-acting insulin aspart in continuous subcutaneous insulin infusion in adults with type 1 diabetes (onset 5). <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 961-967.	2.2	59
33	The effect of diabetes on mortality in critically ill patients: a systematic review and meta-analysis. <i>Critical Care</i> , 2011, 15, R205.	2.5	56
34	Neonatal Hypoglycemia Following Diet-Controlled and Insulin-Treated Gestational Diabetes Mellitus. <i>Diabetes Care</i> , 2018, 41, 1385-1390.	4.3	52
35	The long-term effect of energy restricted diets for treating obesity. <i>Obesity</i> , 2015, 23, 1529-1538.	1.5	51
36	Impact of Liraglutide on Amylase, Lipase, and Acute Pancreatitis in Participants With Overweight/Obesity and Normoglycemia, Prediabetes, or Type 2 Diabetes: Secondary Analyses of Pooled Data From the SCALE Clinical Development Program. <i>Diabetes Care</i> , 2017, 40, 839-848.	4.3	49

#	ARTICLE	IF	CITATIONS
37	Relationship Between Interstitial And Blood Glucose in Type 1 Diabetes Patients: Delay And The Push-Pull Phenomenon Revisited. <i>Diabetes Technology and Therapeutics</i> , 2007, 9, 169-175.	2.4	48
38	No Relevant Relationship between Glucose Variability and Oxidative Stress in Well-Regulated Type 2 Diabetes Patients. <i>Journal of Diabetes Science and Technology</i> , 2011, 5, 86-92.	1.3	48
39	A Review of Safety and Design Requirements of the Artificial Pancreas. <i>Annals of Biomedical Engineering</i> , 2016, 44, 3158-3172.	1.3	45
40	Fully Closed Loop Glucose Control With a Bihormonal Artificial Pancreas in Adults With Type 1 Diabetes: An Outpatient, Randomized, Crossover Trial. <i>Diabetes Care</i> , 2021, 44, 836-838.	4.3	44
41	Outcome and long-term quality of life after total pancreatectomy (PANORAMA): a nationwide cohort study. <i>Surgery</i> , 2019, 166, 1017-1026.	1.0	43
42	One-year sustained glycemc control and weight reduction in type 2 diabetes after addition of liraglutide to metformin followed by insulin detemir according to HbA1c target. <i>Journal of Diabetes and Its Complications</i> , 2013, 27, 492-500.	1.2	42
43	The Clinical Benefits and Accuracy of Continuous Glucose Monitoring Systems in Critically Ill Patientsâ€”A Systematic Scoping Review. <i>Sensors</i> , 2017, 17, 146.	2.1	42
44	Haemoglobin glycation index and risk for diabetes-related complications in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. <i>Diabetologia</i> , 2018, 61, 780-789.	2.9	42
45	Use of fast-acting insulin aspart in insulin pump therapy in clinical practice. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2039-2047.	2.2	41
46	Adverse side effects of dexamethasone in surgical patients. <i>The Cochrane Library</i> , 0, , .	1.5	40
47	Effects of Hyperglycemia and Diabetes Mellitus on Coagulation and Hemostasis. <i>Journal of Clinical Medicine</i> , 2021, 10, 2419.	1.0	40
48	Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials. <i>Lancet Diabetes and Endocrinology</i> , 2013, 1, 123-131.	5.5	37
49	Long-Term Effects of Oral Antidiabetic Drugs During Pregnancy on Offspring: A Systematic Review and Meta-analysis of Follow-up Studies of RCTs. <i>Diabetes Therapy</i> , 2018, 9, 1811-1829.	1.2	37
50	The role of glucagon-like peptide-1 in reproduction: from physiology to therapeutic perspective. <i>Human Reproduction Update</i> , 2019, 25, 504-517.	5.2	34
51	DPP-4 Inhibitor-Related Pancreatitis: Rare but Real!. <i>Diabetes Care</i> , 2017, 40, 161-163.	4.3	33
52	The haemoglobin glycation index as predictor of diabetes-related complications in the AleCardio trial. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 858-866.	0.8	33
53	Consequences of the COVID-19 pandemic for patients with metabolic diseases. <i>Nature Metabolism</i> , 2021, 3, 289-292.	5.1	33
54	Future of Automated Insulin Delivery Systems. <i>Diabetes Technology and Therapeutics</i> , 2017, 19, S-67-S-72.	2.4	31

#	ARTICLE	IF	CITATIONS
55	Systematic review of incretin therapy during peri-operative and intensive care. <i>Critical Care</i> , 2018, 22, 299.	2.5	31
56	Ultra-rapid BioChaperone Lispro improves postprandial blood glucose excursions vs insulin lispro in a 14-day crossover treatment study in people with type 1 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2627-2632.	2.2	31
57	BioChaperone Lispro versus faster aspart and insulin aspart in patients with type 1 diabetes using continuous subcutaneous insulin infusion: A randomized euglycemic clamp study. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1066-1070.	2.2	31
58	Improved glycaemic control in type 1 diabetes patients following participation per se in a clinical trial? mechanisms and implications. <i>Diabetes/Metabolism Research and Reviews</i> , 2003, 19, 357-362.	1.7	28
59	Liraglutide for perioperative management of hyperglycaemia in cardiac surgery patients: a multicentre randomized superiority trial. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 557-565.	2.2	28
60	New-onset diabetes after pancreatoduodenectomy: A systematic review and meta-analysis. <i>Surgery</i> , 2018, 164, 6-16.	1.0	27
61	Microcirculation and its relation to continuous subcutaneous glucose sensor accuracy in cardiac surgery patients in the intensive care unit. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2013, 146, 1283-1289.	0.4	25
62	Accuracy of Intra-arterial and Subcutaneous Continuous Glucose Monitoring in Postoperative Cardiac Surgery Patients in the ICU. <i>Journal of Diabetes Science and Technology</i> , 2015, 9, 663-667.	1.3	23
63	Assessing the Accuracy of Continuous Glucose Monitoring (CGM) Calibrated With Capillary Values Using Capillary or Venous Glucose Levels as a Reference. <i>Journal of Diabetes Science and Technology</i> , 2016, 10, 876-884.	1.3	23
64	Efficacy of total pancreatectomy with islet autotransplantation on opioid and insulin requirement in painful chronic pancreatitis: A systematic review and meta-analysis. <i>Surgery</i> , 2019, 166, 263-270.	1.0	23
65	Continuous Glucose Monitoring. <i>Journal of Diabetes Science and Technology</i> , 2016, 10, 1251-1258.	1.3	22
66	Glycemic Effects of a Low-Carbohydrate Enteral Formula Compared With an Enteral Formula of Standard Composition in Critically Ill Patients: An Open-Label Randomized Controlled Clinical Trial. <i>Journal of Parenteral and Enteral Nutrition</i> , 2018, 42, 1035-1045.	1.3	22
67	Acceptability of Implantable Continuous Glucose Monitoring Sensor. <i>Journal of Diabetes Science and Technology</i> , 2018, 12, 634-638.	1.3	22
68	Tu1502 Longitudinal Monitoring of Lipase and Amylase in Adults With Type 2 Diabetes and Obesity: Evidence From Two Phase 3 Randomized Clinical Trials With the Once-Daily GLP-1 Analog Liraglutide. <i>Gastroenterology</i> , 2012, 142, S-850-S-851.	0.6	21
69	Preoperative considerations of new long-acting glucagon-like peptide-1 receptor agonists in diabetes mellitus. <i>British Journal of Anaesthesia</i> , 2021, 126, 567-571.	1.5	21
70	New Long-Acting Insulin Analogs: From Clamp Studies to Clinical Practice. <i>Diabetes Care</i> , 2015, 38, 541-543.	4.3	21
71	Patch Pump Versus Conventional Pump: Postprandial Glycemic Excursions and the Influence of Wear Time. <i>Diabetes Technology and Therapeutics</i> , 2013, 15, 575-579.	2.4	20
72	Poor Agreement of Computerized Calculators for Mean Amplitude of Glycemic Excursions. <i>Diabetes Technology and Therapeutics</i> , 2014, 16, 72-75.	2.4	18

#	ARTICLE	IF	CITATIONS
73	Use of an Intravascular Fluorescent Continuous Glucose Sensor in ICU Patients. <i>Journal of Diabetes Science and Technology</i> , 2015, 9, 762-770.	1.3	18
74	ADO09, a formulation of the amylin analogue pramlintide and the insulin analogue A21G, lowers postprandial blood glucose versus insulin lispro in type 1 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 961-970.	2.2	18
75	Nocturnal hypoglycaemia in type 1 diabetes? consequences and assessment. <i>Diabetes/Metabolism Research and Reviews</i> , 2004, 20, S43-S46.	1.7	17
76	Continuous Intraperitoneal Insulin Infusion Versus Subcutaneous Insulin Therapy in the Treatment of Type 1 Diabetes: Effects on Glycemic Variability. <i>Diabetes Technology and Therapeutics</i> , 2015, 17, 379-384.	2.4	17
77	Sex differences in cardiometabolic risk factors, pharmacological treatment and risk factor control in type 2 diabetes: findings from the Dutch Diabetes Pearl cohort. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e001365.	1.2	17
78	Day-to-day fasting self-monitored blood glucose variability is associated with risk of hypoglycaemia in insulin-treated patients with type 1 and type 2 diabetes: A post hoc analysis of the SWITCH Trials. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 622-630.	2.2	15
79	Lower rates of hypoglycaemia in older individuals with type 2 diabetes using insulin degludec versus insulin glargine U100: Results from SWITCH 2. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1634-1641.	2.2	14
80	Continuous Glucose Monitoring in Patients with Type 1 Diabetes and Impaired Awareness of Hypoglycemia: Also Effective in Patients with Psychological Distress?. <i>Diabetes Technology and Therapeutics</i> , 2017, 19, 595-599.	2.4	13
81	The International Diabetes Closed-Loop Study: Testing Artificial Pancreas Component Interoperability. <i>Diabetes Technology and Therapeutics</i> , 2019, 21, 73-80.	2.4	13
82	Higher glucose variability in type 1 than in type 2 diabetes patients admitted to the intensive care unit: A retrospective cohort study. <i>Journal of Critical Care</i> , 2017, 38, 300-303.	1.0	11
83	Achieving glycaemic control without weight gain, hypoglycaemia, or gastrointestinal adverse events in type 2 diabetes in the SUSTAIN clinical trial programme. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2426-2434.	2.2	11
84	Prophylactic total pancreatectomy in individuals at high risk of pancreatic ductal adenocarcinoma (PROPAN): systematic review and shared decision-making programme using decision tables. <i>United European Gastroenterology Journal</i> , 2020, 8, 865-877.	1.6	11
85	A Patient-level Analysis of Efficacy and Hypoglycaemia Outcomes Across Treat-to-target Trials with Insulin Glargine Added to Oral Antidiabetes Agents in People with Type 2 Diabetes. <i>European Endocrinology</i> , 2010, 10, 23.	0.8	11
86	Continuous glucose monitoring: coming of age?. <i>European Journal of Endocrinology</i> , 2012, 166, 1-4.	1.9	10
87	Perioperative Hyperglycemia and Glucose Variability in Gynecologic Laparotomies. <i>Journal of Diabetes Science and Technology</i> , 2016, 10, 145-150.	1.3	10
88	Venous, Arterialized-Venous, or Capillary Glucose Reference Measurements for the Accuracy Assessment of a Continuous Glucose Monitoring System. <i>Diabetes Technology and Therapeutics</i> , 2017, 19, 609-617.	2.4	10
89	Long-term quality of life and exocrine and endocrine insufficiency after pancreatic surgery: a multicenter, cross-sectional study. <i>Hpb</i> , 2021, 23, 1722-1731.	0.1	10
90	Acceptance of the Artificial Pancreas: Comparing the Effect of Technology Readiness, Product Characteristics, and Social Influence Between Invited and Self-Selected Respondents. <i>Journal of Diabetes Science and Technology</i> , 2019, 13, 899-909.	1.3	9

#	ARTICLE	IF	CITATIONS
91	Study protocol of a randomised controlled trial comparing perioperative intravenous insulin, GIK or GLP-1 treatment in diabetes – PILGRIM trial. BMC Anesthesiology, 2014, 14, 91.	0.7	8
92	AP@home. Journal of Diabetes Science and Technology, 2016, 10, 950-958.	1.3	8
93	The relation between HbA1c and hypoglycemia revisited; a secondary analysis from an intervention trial in patients with type 1 diabetes and impaired awareness of hypoglycemia. Journal of Diabetes and Its Complications, 2018, 32, 100-103.	1.2	8
94	Study protocol of the randomised placebo-controlled GLOBE trial: GLP-1 receptor antagonism and risk reduction of hyperglycemia during cardiac surgery. BMJ Open, 2018, 8, e022189.	0.8	8
95	The association of intravenous insulin and glucose infusion with intensive care unit and hospital mortality: a retrospective study. Annals of Intensive Care, 2019, 9, 29.	2.2	8
96	Glucagon-like peptide-1, a matter of taste?. Reviews in Endocrine and Metabolic Disorders, 2021, 22, 763-775.	2.6	8
97	Intensive insulin therapy for type 2 diabetes at diagnosis. Lancet Diabetes and Endocrinology, 2013, 1, 3-4.	5.5	7
98	The artificial pancreas – ready for prime time?. Lancet Diabetes and Endocrinology, 2017, 5, 238-239.	5.5	7
99	Lowering blood glucose during hip surgery does not influence coagulation activation. BBA Clinical, 2015, 3, 227-232.	4.1	6
100	SUGAR-DIP trial: oral medication strategy versus insulin for diabetes in pregnancy, study protocol for a multicentre, open-label, non-inferiority, randomised controlled trial. BMJ Open, 2019, 9, e029808.	0.8	6
101	Variability of insulin degludec and glargine 300 U/mL: A matter of methodology or just marketing?. Diabetes, Obesity and Metabolism, 2018, 20, 2051-2056.	2.2	5
102	Better glycaemic control with BioChaperone glargine lispro co-formulation than with insulin lispro Mix25 or separate glargine and lispro administrations after a test meal in people with type 2 diabetes. Diabetes, Obesity and Metabolism, 2019, 21, 1570-1575.	2.2	5
103	Comparison of perioperative glucose regulation in patients with type 1 vs type 2 diabetes mellitus: A retrospective cross-sectional study. Acta Anaesthesiologica Scandinavica, 2019, 63, 314-321.	0.7	5
104	Effects of Liraglutide on Myocardial Function After Cardiac Surgery: A Secondary Analysis of the Randomised Controlled GLOBE Trial. Journal of Clinical Medicine, 2020, 9, 673.	1.0	4
105	Less common types of diabetes mellitus: Incidence and glucose control in the perioperative setting. Journal of Clinical Anesthesia, 2021, 75, 110460.	0.7	2
106	Will Long Acting Insulin Analogs Influence the Use of Insulin Pump Therapy in Type 1 Diabetes?. Current Diabetes Reviews, 2005, 1, 23-26.	0.6	1
107	Glucose Sensing Issues for the Artificial Pancreas. Journal of Diabetes Science and Technology, 2008, 2, 732-734.	1.3	1
108	Postprandial or Fasting Hyperglycemia: Time to Move On?. Diabetes Technology and Therapeutics, 2015, 17, 441-442.	2.4	1

#	ARTICLE	IF	CITATIONS
109	The prevalence of cardiovascular autonomic neuropathy and its influence on post induction hemodynamic variables in patients with and without diabetes; A prospective cohort study. PLoS ONE, 2018, 13, e0207384.	1.1	1
110	Combining Insulin Pumps and Continuous Glucose Monitors; Where Are We to Go from Here?. Journal of Diabetes Science and Technology, 2008, 2, 261-262.	1.3	0
111	PS12 - 62. Continuous glucose monitoring accuracy assessed at home is seemingly better than when assessed at the clinical research centre. Nederlands Tijdschrift Voor Diabetologie, 2011, 9, 133-133.	0.0	0
112	PS17 - 83. A systematic review and meta-analysis of the diagnostic accuracy of continuous glucose monitoring systems for hypoglycaemia detection. Nederlands Tijdschrift Voor Diabetologie, 2012, 10, 158-158.	0.0	0
113	In response to: Metformin for the management of perioperative hyperglycaemia. Diabetes, Obesity and Metabolism, 2018, 20, 755-755.	2.2	0
114	Cover Image, Volume 23, Issue 4. Diabetes, Obesity and Metabolism, 2021, 23, .	2.2	0
115	A Classification Algorithm for Types of Diabetes in Chronic Pancreatitis Using Epidemiological Characteristics. Pancreas, 2021, 50, 1407-1414.	0.5	0